| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04639843 Details | 2022-11-04 Interventional | 1 | 0 | Azacitidine Cc-486 Doxorubicin Romidepsin Enteropathy-Ass… Leukemia, T-Cel… Leukemia-Lympho… Lymphoma Lymphoma, Extra… Lymphoma, T-Cel… Lymphoma, T-Cel… Adult T-cell Le… Extranodal NK-/… Hepatosplenic T… Monomorphic Epi… | Safety issues with PI3 kinase inhibitors - | |||
| NCT04242173 Details | 2022-11-04 Interventional | 2 | 3 | Cemiplimab Carcinoma Carcinoma, Squa… Squamous Cell C… Cutaneous Squam… Cutaneous Squam… | Lack of Interest - | |||
| NCT04135352 2020-003431-25 Details | 2022-11-04 Interventional | 1 | 35 | Pembrolizumab Neoplasm Metast… | Business Reasons - | |||
| NCT03518112 Details | 2022-11-04 Interventional | 2 | 6 | Antibodies Antibodies, Bis… Antibodies, Mon… Antineoplastic … BB 1101 Blinatumomab Calcium Calcium, Dietar… Cyclophosphamid… Cytarabine Dexamethasone Dexamethasone a… Folic Acid Immunoglobulins Lenograstim Leucovorin Levoleucovorin Mercaptopurine Methotrexate Muromonab-CD3 Rituximab Vincristine Leukemia Leukemia, Lymph… Philadelphia Ch… Precursor Cell … Philadelphia Ch… Recurrent B Acu… Refractory B Ac… | Due to Competing Studies - | |||
| NCT03145558 Details | 2022-11-04 Interventional | 2 | - | Doxorubicin Tirapazamine Carcinoma Carcinoma, Hepa… | on hold by sponsor - | |||
| NCT02574156 Details | 2022-11-04 Interventional | 3 | [8 Refs] | 500 | Insulin Hyperglycemia | Finished - | ||
| NCT02380118 Details | 2022-11-04 Interventional | 4 | 167 | Haloperidol Haloperidol dec… Midazolam Olanzapine Emergencies Psychomotor Agi… Acute Agitation… | Primary endpoint reached based on data projection from interim analysis. - | |||
| NCT03430063 2017-003684-35 Details | 2022-11-03 Interventional | 2 | 28 | Cemiplimab Ipilimumab Carcinoma, Non-… Advanced Non-Sm… | Business decision All participants' tumors had PD-L1 expression levels of <50% at baseline. Therefore, the results do not present efficacy for participants with PD-L1 expression levels of ≥50% of tumor cells versus all participants. | |||
| NCT03035838 Details | 2022-11-03 Interventional | 1 | 0 | Aprepitant Fosaprepitant Brain Injuries Brain Injuries,… Intracranial Hy… Wounds and Inju… Traumatic Brain… | Alternate study commenced using different drug - | |||
| NCT02374853 Details | 2022-11-03 Interventional | 2 | 1037 | Vancomycin Communicable Di… Infections Wound Infection INFECTION | the preliminary analysis of study result did not show significant benefit that was anticipate - | |||
| NCT01244256 Details | 2022-11-03 Interventional | 2/3 | - | Beclomethasone Clotrimazole Gentamicins Miconazole Folliculitis | - - | |||
| NCT01229072 Details | 2022-11-03 Interventional | 2/3 | - | Calcium heparin Heparin Kidney Failure,… Renal Insuffici… Renal Insuffici… Chronic Renal F… | - - | |||
| NCT01228656 Details | 2022-11-03 Interventional | 2 | 40 | Mometasone Furo… Salicylates Salicylic Acid Psoriasis Plaque Psoriasi… | - - | |||
| NCT01086982 Details | 2022-11-03 Interventional | 1 | - | Octreotide Acromegaly | - - | |||
| NCT00717652 Details | 2022-11-03 Interventional | 2/3 | - | Tretinoin Triamcinolone Melanosis Melasma | - - | |||
| NCT04465916 Details | 2022-11-02 Interventional | 2 | 26 | Entecavir Tenofovir Hepatitis Hepatitis B Hepatitis B, Ch… | DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized
subjects were followed up to W40. - | |||
| NCT01666249 Details | 2022-11-02 Interventional | 3 | - | Antibodies Immunoglobulins Immunoglobulins… Fetomaternal Tr… Hemorrhage Pregnancy; Feto… | Suspended for indetermined period. - | |||
| NCT01558115 Details | 2022-11-02 Interventional | 4 | 8 | Denosumab Hyperparathyroi… Hyperparathyroi… Primary Hyperpa… | Poor enrollment Data was not collected and analyzed as per protocol due to study closing prematurely because of poor enrollment. | |||
| NCT03024437 Details | 2022-11-01 Interventional | 1/2 | - | Atezolizumab Bevacizumab Entinostat Carcinoma, Rena… Kidney Neoplasm… Metastatic Canc… Renal Cancer | Major review underway - | |||
| NCT00969397 Details | 2022-11-01 Interventional | 1/2 | 0 | Angiogenesis In… Hemangioma, Cap… Port-Wine Stain Port Wine Stain | We have decided not to pursue the study - |